BSECompany Update6d ago · 13 Aug 2026, 06:07 pm

Transcript of Earning Call held on 7th August, 2026

Godavari Biorefineries Ltd · 544279

✦ AI SummaryResults

Godavari Biorefineries Ltd has announced the transcript of its Q1 FY 27 earnings conference call, highlighting the company's operational and financial performance amidst a dynamic global environment. The company has successfully commissioned a 200 kilolitres per day grain-based distillery, taking its total distillery capacity to 800 kilolitres per day. The company is evaluating the addition of 160 kilolitres per day fungible capacity within the existing capacity to enhance its flexibility in optimizing between sugar and ethanol production.

Analysis Scores

Earnings Impact6/10
Growth Catalyst4/10
Governance Concern1/10
Regulatory Risk2/10
Balance Sheet Risk3/10
Liquidity Impact7/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Godavari Biorefineries Ltd - 544279 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

Attachments (1)

📄

804caf00-9ede-472f-9da9-fb450327464b.pdf

pdf

Download →
View document text
Dated: August 13, 2026 The Manager The Manager Listing Department Listing Department National Stock Exchange of India Limited BSE Limited Exchange Plaza, C-1, Block G, Phiroze Jeejeebhoy Tower, Bandra Kurla Complex, Bandra (E), Dalal Street Mumbai – 400 051 Mumbai-400001 Script Symbol: GODAVARIB Script Code:544279 Sub: Transcript of Investor/Analyst Conference Call held for discussion of financial performance of Q1 FY 27 Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to forward herewith a link to the Transcript of Investor's/Analyst/Concall on financial results of the Company for Q1 FY 27 held on 7th August 2026. The same has been uploaded on the website of the Company at the link below https://www.godavaribiorefineries.com/sites/default/files/Transcript_Q1FY27.pdf This is for your information and records. Thanking you, Yours faithfully For Godavari Biorefineries Limited Manoj Jain Company Secretary & Compliance O(cid:431)icer Membership No. F-7998 “Godavari Biorefineries Limited Q1 FY'27 Earnings Conference Call” August 07, 2026 MANAGEMENT: MR. SAMIR SOMAIYA – CHAIRMAN AND MANAGING DIRECTOR – GODAVARI BIOREFINERIES LIMITED MR. ASHISH SINHA – DEPUTY GENERAL MANAGER, INVESTOR RELATIONS AND FINANCE – GODAVARI BIOREFINERIES LIMITED MODERATOR: MS. PRACHI AMBRE – MUFG INTIME INDIA PRIVATE LIMITED Page 1 of 14 Godavari Biorefineries Limited August 07, 2026 Moderator: Ladies and gentlemen, good day and welcome to Godavari Biorefineries Limited Q1 FY27 Earnings Conference Call. As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during this conference call, please signal an operator by pressing star then zero on a touchtone phone. Please note that this conference is being recorded. I now hand the conference over to Ms. Prachi Ambre from MUFG Investor Relations. Thank you and over to you, ma'am. Prachi Ambre: Thank you, Sumit. Good morning, everyone, and welcome to Godavari Biorefineries Limited Q1 FY27 Earnings Conference Call. Today on the call, we have Mr. Samir Somaiya, Chairman and Managing Director, Mr. Ashish Sinha, Deputy General Manager, Investor Relations and Finance, to provide insights on the operational and financial performance. Before we begin the call, I would like to give a short disclaimer. This call may contain some of the forward-looking statements which are completely based upon our beliefs and expectations as of today. The statements are not a guarantee of our future performance and involve unforeseen risks and uncertainties. With this, I would like to hand over the call to Samir sir for his opening remarks. Over to you, sir. Thank you. Samir Somaiya: Good morning, everyone. Thank you for joining us today for the Q1 FY27 earnings call of Godavari Biorefineries Limited. We appreciate your continued trust, engagement, and interest in our company. At the outset, let me briefly set the broader global context. The global operating environment continues to remain dynamic, with geopolitical developments, volatility in energy and raw material markets, and evolving trade flows creating challenges across industry. In these past few months, we have transported into a world where fossil resources have become scarce, higher oil prices, and this underscores the fact that the work we are doing is even more relevant today, especially in the geopolitical context that we see. At the same time, the transition towards bio-based and sustainable alternatives continue to gain momentum, as businesses are increasingly focusing on energy security, supply chain resilience, and more sustainable solutions. Global supply tightness is also reinforcing the importance of reliable, captive, bio-based production and supply, with increasing preference for dependable supply partners across local and export markets. In India, the successful rollout of E20 and the continued policy focus on higher ethanol blending are supporting the long-term demand outlook for renewable fuels. The government has come out with new draft guidelines for E85 and E100 to be used as a fuel. This will lead to these fuels coming out in the market sooner rather than later and reflect the government's direction for the country to be more self-reliant in energy. A key milestone during the quarter was the successful commissioning of our 200 kilolitres per day grain-based distillery at Sameerwadi, taking our total distillery capacity to 800 kilolitres per day. This furthers our goal for being an integrated biorefinery model where we can combine bio- based chemicals, sugar, and ethanol with flexibility to respond to the changing market conditions and capture opportunities across the value chain. Page 2 of 14 Godavari Biorefineries Limited August 07, 2026 Having an additional feedstock of maize/grain gives us additional flexibility to manage volatility in product prices, feedstock costs, climate effects, and possible policy changes. The prices of sugar have increased in the past few weeks. The prices of ethanol from sugarcane juice have remained the same over the past few years. So, we will continue to look at the economics of sugar and ethanol as we make our choices of diversion. In this context, we are evaluating the addition of 160 kilolitres per day fungible capacity within the existing 800 kilolitres per day capacity. If there is a pivot to more sugar in the coming season, there will be fermentation and distillation capacity that will be available for this grain-to-ethanol conversion. We may need to only add equipment for grain preparation at the front end. This will further enhance our flexibility to optimize between sugar and ethanol depending on market conditions, allowing us to take advantage of favourable sugar economics while retaining the ability to deploy capacity towards ethanol using other feedstock. This flexibility has always been central to our integrated biorefinery model. As markets evolve, we can optimize the allocation of our feedstock and capacity across sugar and ethanol, allowing us to capture opportunities across the value chain. With the next phase of ethanol blending in India and increased sugar price realizations, we believe this flexibility will become increasingly valuable. Coming to the quarter, we have commenced FY27 with resilient performance. Total income for Q1 grew by 4.9% year-on-year. The bio-based chemicals business delivered a strong quarter, with revenue increasing 19.4% year-on-year and EBITDA growing 53% year-on-year. The benefits of the debottlenecking initiatives undertaken earlier are now translating into improved operating efficiencies and profitability. In our integrated sugar, co-generation and ethanol operations, the quarter remained challenging, with feedstock conditions, rising manufacturing costs and ethanol tender allotments putting some pressure on the business. At the same time, improved sugar realizations provide an opportunity to benefit from better sugar economics going forward. Innovation also continues to be an important part of our efforts to build future growth platforms. During the quarter, we secured a Japanese patent for our novel anticancer molecule and filed an application with the CDSCO for preliminary efficacy trials for our triple-negative breast cancer molecule, with trials expected to commence from Q3 FY27, subject to government regulatory approvals. This marks a significant milestone in translating our R&D efforts into potential clinical applications. Overall, the quarter saw encouraging momentum in our bio-based chemicals business, progress in strengthening our ethanol platform, and continued advancement in our innovation-led growth initiatives. We also secured an Indian patent for a cost-effective process to manufacture branched alcohols, further strengthening our intellectual property portfolio. *Disclaimer: Due to tec [Showing first 8,000 characters — download PDF for full document]